Johnson & Johnson Analyst Price Targets - Benzinga

Johnson & Johnson

JNJNYSE

Trade with Public

Trade with Public

$266.70

Dividendo: La fecha límite del dividendo era hace 7 días

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Johnson & Johnson Analyst Price Targets

Wall Street analyst price targets and consensus rating for Johnson & Johnson (JNJ).

Price Target Range — 8 Quarters

Analyst Consensus — 18 Analysts

12Buy

6Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$254Upside to Avg. PT-4.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$270→$287
Aug 3, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$272→$282
Jul 17, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$270
Jul 16, 2026	Raymond James	Jayson Bedford	PT Raise	Outperform	$258→$265
Jul 16, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$287
Jul 16, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$263→$272
Jul 16, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$284→$294
Jul 13, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$250→$300
Jul 13, 2026	RBC Capital	Shagun Singh	PT Raise	Outperform	$265→$287
Jul 10, 2026	B of A Securities	Tim Anderson	PT Raise	Neutral	$254→$263
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$283→$284
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$285→$298
Jun 26, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$266→$270
May 13, 2026	Leerink Partners	David Risinger	Upgrade	Market Perform→Outperform	$265
Apr 15, 2026	Barclays	Matt Miksic	PT Raise	Equal-Weight	$234→$255
Apr 15, 2026	Stifel	Rick Wise	PT Raise	Hold	$220→$250
Apr 15, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$240→$263
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$262→$267
Apr 8, 2026	TD Cowen	Michael Nedelcovych	Assumes	Buy	$250
Mar 30, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$255

More with Benzinga EdgeGet Access

Analyst Ratings News

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

PRO
Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287

Guggenheim analyst Vamil Divan maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $270 to $287.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $282

Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $272 to $282.

Benzinga Newsdesk

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Vandana Singh

PRO
Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $270 Price Target

Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $270 price target.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $265

Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $258 to $265.

Benzinga Newsdesk